Ocular Hypertension Market

DelveInsight’s ‘Ocular Hypertension – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.


The Ocular Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Ocular Hypertension symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Ocular Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Geography Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018–2030

Ocular Hypertension Disease Understanding and Treatment Algorithm

Ocular Hypertension Overview

Ocular hypertension is defined as elevated intraocular pressure (IOP) without evidence of structural or functional damage by standard clinical tests. The patient with OHT must have open angles and no evidence of an ocular or systemic cause of the elevated IOP. Although genetic influences on IOP are being uncovered, genetic testing does not yet influence the diagnosis of OHT. Many different thresholds have been used to define OHT.


The increase in intraocular pressure (progressive with age, although it may also be due to other disorders or causes) is the main risk factor for developing glaucoma, and therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high, but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged - and intraocular pressure might be normal or high - which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.


Prior to diagnosis, a thorough examination must be performed to rule out secondary causes of elevated IOP. Additional risk factors must be considered to estimate each patient’s probability of progression to glaucoma. The decision to initiate treatment should be based on the patient’s risk profile, as well as his or her age, medical status, life expectancy, and preferences. Patients need to be followed for changes such as disc hemorrhages, which suggest an increased risk of progression. Both treated and untreated patients should be followed for structural and functional damage suggestive of glaucoma. If these changes are seen, treatment should be initiated or accelerated.


Ocular Hypertension Diagnosis and Treatment

The current mainstays for OHT treatment includes the use of symptomatic medical care to reduce the intraocular eye pressure followed by surgery in high risk individuals who do not demonstrate positive intraocular control with existing medical care. Topical therapies majorly comprise of beta-blockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics, and miotics.


It covers the details of conventional and current medical therapies, and diagnosis available in the Ocular Hypertension market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States.


The DelveInsight Ocular Hypertension market report gives a thorough understanding of Ocular Hypertension symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Ocular Hypertension symptoms of treatment algorithms and treatment guidelines for Ocular Hypertension symptoms in the United States.

Ocular Hypertension Epidemiology

The epidemiology division’s Ocular Hypertension symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Ocular Hypertension epidemiology segmented as the Prevalent cases of Ocular Hypertension , Gender-specific prevalent case of Ocular Hypertension, Age-specific prevalent cases of Ocular Hypertension and Treated- cases of Ocular Hypertension. The report includes the prevalent scenario of Ocular Hypertension symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Ocular Hypertension Epidemiology

The epidemiology segment also provides the Ocular Hypertension epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total prevalent cases of Ocular Hypertension in the 7MM were 20,817,647 in 2020.

Ocular Hypertension Drug Chapters

The drug chapter segment of the Ocular Hypertension report encloses the detailed analysis of Ocular Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Ocular Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Prostaglandin analogs (PGAs) are recommended as the first-choice treatment for POAG because of their efficacy, limited systemic side effects, and once-daily dosing. These drugs reduce IOP by stimulating aqueous humor drainage, primarily through the uveoscleral outflow pathway. Latanoprost, bimatoprost, travoprost, and tafluprost, all PGF2a analogues, are currently approved for glaucoma therapy in the US and EU. Beta blockers, combination therapies, carbonic anhydrase inhibitors constitute second line of therapy for treatment of OHT.

Products detail in the report…


Ocular Hypertension Emerging Drugs


NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently being developed by Nicox Ophthalmics in Phase II multicenter, clinical study for the lowering of IOP in patients with OAG or OHT in the US.

Ocular Hypertension Market Outlook

The Ocular Hypertension market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Ocular Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Ocular Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Ocular Hypertension market in the 7MM is expected to grow during the study period 2018–2030.


Key Findings

This section includes a glimpse of the Ocular Hypertension market in 7MM. The market size of OHT in the seven major markets was found to be USD 2,735.0 million in 2020 and market is estimated to increase at a CAGR of 3.82% for the study period (2018–2030).


The United States Market Outlook

This section provides a total of Ocular Hypertension market size and market size by therapies in the United States.


The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for Ocular Hypertension are in development, many of which have novel targets and mechanisms of action. Among the prostaglandin analogues, ONO-9054 (Santen Inc.) and NCX470 (Nicox Opthalmics) are in the late development stages.


EU-5 Countries: Market Outlook

The total Ocular Hypertension market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative for the treatment of glaucoma and OHT. This product is in Phase III clinical development stage; Santen recently initiated the Phase III trial in Europe and Asia.


Japan: Market Outlook

The total Ocular Hypertension market size and market size by therapies in Japan are also mentioned.

Ocular Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Ocular Hypertension market uptake by drugs; patient uptake by therapies; and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Ocular Hypertension Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Ocular Hypertension key players involved in developing targeted therapeutics.

Products detail in the report…


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Ocular Hypertension emerging therapies.

Reimbursement Scenario in Ocular Hypertension

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Ocular Hypertension domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Ocular Hypertension market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Ocular Hypertension Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Ocular Hypertension, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Ocular Hypertension epidemiology and treatment in the United States
  • Additionally, an all-inclusive account of both the current and emerging therapies for Ocular Hypertension is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Ocular Hypertension market; historical and forecasted is included in the report, covering drug outreach in the United States
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Ocular Hypertension market

Report Highlights

  • In the coming years, Ocular Hypertension market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Ocular Hypertension. The launch of emerging therapies will significantly impact the Ocular Hypertension market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ocular Hypertension.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Ocular Hypertension Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Ocular Hypertension Pipeline Analysis
  • Ocular Hypertension Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Ocular Hypertension Report Key Strengths

  • 10-Year Forecast
  • The United States Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

Ocular Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Ocular Hypertension Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Ocular Hypertension total market Size as well as market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the market's key findings across 7MM and which country will have the largest Ocular Hypertension market Size during the forecast period (2018–2030)?
  • At what CAGR, the Ocular Hypertension market is expected to grow by 7MM during the forecast period (2018–2030)?
  • What would be the Ocular Hypertension market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Ocular Hypertension market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Ocular Hypertension?
  • What is the historical Ocular Hypertension patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Ocular Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Ocular Hypertension?
  • Out of all 7MM countries, which country would have the highest prevalent population of Ocular Hypertension during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Ocular Hypertension?
  • What are the current treatment guidelines for treating Ocular Hypertension?
  • What are the Ocular Hypertension marketed drugs and their MOA, regulatory milestones, product development activities, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Ocular Hypertension?
  • How many therapies are developed by each company for the treatment of Ocular Hypertension?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Ocular Hypertension?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ocular Hypertension and their status?
  • What are the key designations that have been granted for the emerging therapies for Ocular Hypertension?
  • What are the global historical and forecasted market of Ocular Hypertension?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Ocular Hypertension market
  • To understand the future market competition in the Ocular Hypertension market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Ocular Hypertension in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Ocular Hypertension market
  • To understand the future market competition in the Ocular Hypertension market

1. Key Insights

2. Report Introduction

3. Ocular Hypertension Market Overview at a Glance

3.1. Market Share (%) Distribution of Ocular Hypertension in 2018

3.2. Market Share (%) Distribution of Ocular Hypertension in 2030

4. Executive Summary of Ocular Hypertension

5. Disease Background and Overview

5.1. Introduction

5.2. Causes

5.3. Physiology and pathogenesis

5.4. Morphology

5.5. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of OHT

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Ocular Hypertension in the United States

6.4.2. Gender-specific Prevalence of Ocular Hypertension in the United States

6.4.3. Age-specific Prevalence of Ocular Hypertension in the United States

6.4.4. Treated cases of Ocular Hypertension in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalent Cases of Ocular Hypertension in Germany

6.5.1.2. Gender-specific Prevalence of Ocular Hypertension in Germany

6.5.1.3. Age-specific Prevalence of Ocular Hypertension in Germany

6.5.1.4. Treated cases of Ocular Hypertension in Germany

6.5.2. France

6.5.2.1. Prevalent Cases of Ocular Hypertension in France

6.5.2.2. Gender-specific Prevalence of Ocular Hypertension in France

6.5.2.3. Age-specific Prevalence of Ocular Hypertension in France

6.5.2.4. Treated Cases of Ocular Hypertension in France

6.5.3. Italy

6.5.3.1. Prevalent Cases of Ocular Hypertension in Italy

6.5.3.2. Gender-specific Prevalence of Ocular Hypertension in Italy

6.5.3.3. Age-specific Prevalence of Ocular Hypertension in Italy

6.5.3.4. Treated Cases of Ocular Hypertension in Italy

6.5.4. Spain

6.5.4.1. Prevalent Cases of Ocular Hypertension in Spain

6.5.4.2. Gender-specific Prevalence of Ocular Hypertension in Spain

6.5.4.3. Age-specific Prevalence of Ocular Hypertension in Spain

6.5.4.4. Treated cases of Ocular Hypertension in Spain

6.5.5. United Kingdom

6.5.5.1. Prevalent Cases of Ocular Hypertension in the United Kingdom

6.5.5.2. Gender-specific Prevalence of Ocular Hypertension in the United Kingdom

6.5.5.3. Age-specific Prevalence of Ocular Hypertension in the United Kingdom

6.5.5.4. Treated Cases of Ocular Hypertension in the United Kingdom

6.6. Japan

6.6.1. Prevalent Cases of Ocular Hypertension in Japan

6.6.2. Gender-specific Prevalence of Ocular Hypertension in Japan

6.6.3. Age-specific Prevalence of Ocular Hypertension in Japan

6.6.4. Treated Cases of Ocular Hypertension in Japan

7. Treatment

7.1. Frequency and follow-up

7.2. Uncertainties regarding best practice for managing ocular hypertension

7.3. Progression to Glaucoma

8. NICE Recommendations and Guidelines

8.1. Case-finding

8.2. Diagnosis

8.3. Standard practice for all assessments

8.4. Reassessment tests

8.5. Treatment

8.6. Stopping treatment for people with OHT or suspected COAG

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1. Key Cross- Marketed therapies

11.2. Travoprost ophthalmic solution: Novartis

11.2.1. Product Description

11.2.2. Mechanism of action

11.2.3. Regulatory Milestones

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Vyzulta (latanoprostene bunod ophthalmic solution): Bausch and Lomb Incorporated

11.3.1. Product Description

11.3.2. Mechanism of action

11.3.3. Regulatory Milestones

11.3.4. Clinical Development

11.3.5. Clinical Trials Information

11.3.6. Safety and Efficacy

11.3.7. Product Profile

11.4. Zioptan: Merck Sharp and Dohme

11.4.1. Product Description

11.4.2. Mechanism of action

11.4.3. Regulatory Milestones

11.4.4. Clinical Development

11.4.5. Clinical Trials Information

11.4.6. Safety and Efficacy

11.4.7. Product Profile

11.5. Rhopressa: Aerie Pharmaceuticals

11.5.1. Product Description

11.5.2. Mechanism of action

11.5.3. Regulatory Milestones

11.5.4. Clinical Development

11.5.5. Clinical Trials Information

11.5.6. Safety and Efficacy

11.5.7. Product Profile

11.6. DURYSTA: Abbvie

11.6.1. Product Description

11.6.2. Mechanism of action

11.6.3. Regulatory Milestones

11.6.4. Clinical Development

11.6.5. Clinical Trials Information

11.6.6. Efficacy of Durysta

11.6.7. Product Profile

11.7. Rocklatan: Aerie Pharmaceutical

11.7.1. Product Description

11.7.2. Mechanism of action

11.7.3. Regulatory Milestones

11.7.4. Clinical Development

11.7.5. Clinical Trials Information

11.7.6. Safety and Efficacy of Rocklatan

11.7.7. Product Profile

11.8. LUMIGAN: Allergan plc

11.8.1. Product Description

11.8.2. Mechanism of action

11.8.3. Regulatory Milestones

11.8.4. Safety and efficacy

11.8.5. Product Profile

11.9. Betaxon: Alcon Laboratories, Inc.

11.9.1. Product Description

11.9.2. Mechanism of action

11.9.3. Regulatory Milestones

11.9.4. Safety and Efficacy

11.9.5. Product Profile

11.10. COSOPT: Merck Sharp & Dohme Corp.

11.10.1. Product Description

11.10.2. Mechanism of action

11.10.3. Regulatory Milestones

11.10.4. Safety and Efficacy

11.10.5. Product Profile

11.11. Rescula: Ciba Vision

11.11.1. Product Description

11.11.2. Regulatory Milestones

11.11.3. Safety and Efficacy of Rescula

11.11.4. Product Profile

11.12. Alphagan P: Abbvie

11.12.1. Product Description

11.12.2. Mechanism of action

11.12.3. Regulatory Milestones

11.12.4. Safety and Efficacy of Alphagan

11.12.5. Product Profile

11.13. Xelpros: Sun Pharma Advanced Research Company Limited

11.13.1. Product Description

11.13.2. Mechanism of action

11.13.3. Regulatory Milestones

11.13.4. Safety and Efficacy

11.13.5. Product Profile

11.14. Tapcom/ DE-111: Santen Pharmaceutical Co., Ltd.

11.14.1. Product Description

11.14.2. Regulatory Milestones

11.14.3. Product Profile

11.15. Simbrinza: Alcon Research

11.15.1. Product Description

11.15.2. Mechanism of action

11.15.3. Regulatory Milestones

11.15.4. Clinical Development

11.15.5. Clinical Trials Information

11.15.6. Safety and Efficacy

11.15.7. Product Profile

11.16. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa Ltd.

11.16.1. Product Description

11.16.2. Mechanism of action

11.16.3. Regulatory Milestones

11.16.4. Safety and Efficacy

11.16.5. Product Profile

11.17. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research

11.17.1. Product Description

11.17.2. Mechanism of action

11.17.3. Regulatory Milestones

11.17.4. Clinical Development

11.17.5. Clinical Trials Information

11.17.6. Safety and Efficacy

11.17.7. Product Profile

11.18. Combigan: Allergan

11.18.1. Product Description

11.18.2. Mechanism of action

11.18.3. Regulatory Milestones

11.18.4. Safety and Efficacy of COMBIGAN

11.18.5. Product Profile

11.19. Azarga: Novartis

11.19.1. Product Description

11.19.2. Mechanism of action

11.19.3. Regulatory Milestones

11.19.4. Safety and Efficacy

11.19.5. Product Profile

11.20. Ganfort: Allergan

11.20.1. Product Description

11.20.2. Mechanism of action

11.20.3. Regulatory Milestones

11.20.4. Safety and Efficacy of Ganfort

11.20.5. Product Profile

11.21. Mikeluna: Otsuka Pharmaceuticals

11.21.1. Product Description

11.21.2. Mechanism of action

11.21.3. Regulatory Milestones

11.21.4. Clinical Development

11.21.5. Product Profile

11.22. AILAMIDE: Senju Pharmaceuticals

11.22.1. Product Description

11.22.2. Mechanism of action

11.22.3. Regulatory Milestones

11.22.4. Clinical Development

11.22.5. Product Profile

11.23. Aibeta: Senju Pharmaceuticals

11.23.1. Product Description

11.23.2. Regulatory Milestones

11.23.3. Product Profile

12. Emerging Therapies

12.1. DE-130A (latanoprost): Santen Pharmaceutical

12.1.1. Drug Description

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Product Profile

12.2. NCX 470: Nicox Ophthalmics

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. Bamosiran (SYL040012): Sylentis

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Safety and Efficacy

12.3.6. Product Profile

12.4. Nyxol (Phentolamine Mesylate): Ocuphire Pharma

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Safety and Efficacy

12.4.6. Product Profile

12.5. POLAT-001: Peregrine Ophthalmic

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.4. Clinical Trials Information

12.5.5. Safety and Efficacy

12.5.6. Product Profile

12.6. Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical

12.6.1. Drug Description

12.6.2. Regulatory Milestones

12.6.3. Clinical Development

12.6.4. Clinical Trials Information

12.6.5. Safety and Efficacy

12.6.6. Product Profile

12.7. ENV515 (Travoprost XR): Envisia Therapeutics

12.7.1. Drug Description

12.7.2. Regulatory Milestones

12.7.3. Clinical Development

12.7.4. Clinical Trials Information

12.7.5. Safety and Efficacy

12.7.6. Product Profile

12.8. PRO-122: Laboratorios Sophia S.A de C.V.

12.8.1 Drug Description

12.8.2. Clinical Development

12.8.3. Clinical Trials Information

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. DE-117: Santen Inc.

12.9.1. Drug Description

12.9.2. Regulatory Milestones

12.9.3. Clinical Development

12.9.4. Clinical Trials Information

12.9.5. Safety and Efficacy

12.9.6. Product Profile

12.10. PDP-716: Sun Pharma

12.10.1. Drug Description

12.10.2. Clinical Development

12.10.3. Clinical Trials Information

12.10.4. Safety and Efficacy of PDP-716

12.10.5. Product Profile

12.11. QLS-101: Qlaris Bio

12.11.1. Drug Description

12.11.2. Regulatory Milestones

12.11.3. Clinical Development

12.11.4. Clinical Trials Information

12.11.5. Product Profile

12.12. ST266: Noveome

12.12.1. Drug Description

12.12.2. Clinical Development

12.12.3. Clinical Trials Information

12.12.4. Product Profile

13. Ocular Hypertension: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Ocular Hypertension in 7MM

13.3. Market Size of Ocular Hypertension by Therapies by class

13.4. Market Size of Ocular Hypertension for Emerging Therapies by class

13.5. Market Outlook

13.6. United States Market Size

13.6.1. Total Market Size of Ocular Hypertension in United States

13.6.2. Market Size of Ocular Hypertension of Therapies by class in United States

13.6.3. Market Size of Ocular Hypertension for Emerging Therapies in United States

13.7. EU-5 Market Size

13.7.1. Germany

13.7.1.1. Total Market size of Ocular Hypertension in Germany

13.7.1.2. Market Size of Ocular Hypertension of Therapies by Class in Germany

13.7.1.3. Market Size of Ocular Hypertension for Emerging Therapies in Germany

13.7.2. France

13.7.2.1. Total Market size of Ocular Hypertension in France

13.7.2.2. Market Size of Ocular Hypertension by Therapies in France

13.7.2.3. Market Size of Ocular Hypertension for Emerging Therapies in France

13.7.3. Italy

13.7.3.1. Total Market size of Ocular Hypertension in Italy

13.7.3.2. Market Size of Ocular Hypertension of Therapies by class in Italy

13.7.3.3. Market Size of Ocular Hypertension of Emerging Therapies in Italy

13.7.4. Spain

13.7.4.1. Total Market size of Ocular Hypertension in Spain

13.7.4.2. Market Size of Ocular Hypertension of Therapies by class in Spain

13.7.4.3. Market Size of Ocular Hypertension for Emerging Therapies in Spain

13.7.5. United Kingdom

13.7.5.1. Total Market size of Ocular Hypertension in United Kindgom

13.7.5.2. Market Size of Ocular Hypertension of Therapies by class in United Kingdom

13.7.5.3. Market Size of Ocular Hypertension for Emerging Therapies in United Kingdom

13.8. Japan

13.8.1. Total Market size of Ocular Hypertension in Japan

13.8.2. Market Size of Ocular Hypertension of Therapies by Class in Japan

13.8.3. Market Size of Ocular Hypertension for Emerging Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Ocular Hypertension, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Prevalent Patient Population of Ocular Hypertension in 7MM (2018–2030)

Table 3: Prevalent Cases of Ocular Hypertension in the United States (2018–2030)

Table 4: Gender-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Table 5: Age-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Table 6: Treated Cases of Ocular Hypertension in the United States (2018–2030)

Table 7: Prevalent Cases of Ocular Hypertension in Germany (2018–2030)

Table 8: Gender-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Table 9: Age-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Table 10: Diagnosed Cases of Ocular Hypertension in Germany (2018–2030)

Table 11: Prevalent Cases of Ocular Hypertension in France (2018–2030)

Table 12: Gender-specific Prevalence of Ocular Hypertension in France (2018–2030)

Table 13: Age-specific Prevalence of Ocular Hypertension in France (2018–2030)

Table 14: Treated Cases of Ocular Hypertension in France (2018–2030)

Table 15: Prevalent Cases of Ocular Hypertension in Italy (2018–2030)

Table 16: Gender-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Table 17: Age-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Table 18: Diagnosed Cases of Ocular Hypertension in Italy (2018–2030)

Table 19: Prevalent Cases of Ocular Hypertension in Spain (2018–2030)

Table 20: Gender-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Table 21: Age-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Table 22: Treated Cases of Ocular Hypertension in Spain (2018–2030)

Table 23: Prevalent Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Table 24: Gender-specific Prevalence of Ocular Hypertension in the United Kingdom in 000’s (2018–2030)

Table 25: Age-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Table 26: Treated Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Table 27: Prevalent Cases of Ocular Hypertension in Japan (2018–2030)

Table 28: Gender-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Table 29: Age-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Table 30: Treated Cases of Ocular Hypertension in Japan (2018–2030)

Table 31: Vyzulta, Clinical Trial Description, 2021

Table 32: Zioptan Clinical Trial Description, 2021

Table 33: RHOPRESSA, Clinical Trial Description, 2021

Table 34: Durysta, Clinical Trial Description, 2021

Table 35: Rocklatan, Clinical Trial Description, 2021

Table 36: Simbrinza Clinical Trial Description, 2021

Table 37: DuoTrav Clinical Trial Description, 2021

Table 38: DE-130A, Clinical Trial Description, 2021

Table 39: NCX 470, Clinical Trial Description, 2021

Table 40: SYL040012 (Bamosiran), Clinical Trial Description, 2020

Table 41: Nyxol, Clinical Trial Description, 2021

Table 42: POLAT-001, Clinical Trial Description, 2019

Table 43: Sepetaprost, Clinical Trial Description, 2021

Table 44: ENV515 Travoprost XR, Clinical Trial Description, 2019

Table 45: PRO-122, Clinical Trial Description, 2021

Table 46: DE-117, Clinical Trial Description, 2021

Table 47: PDP 716, Clinical Trial Description, 2021

Table 48: QLS-101, Clinical Trial Description, 2021

Table 49: ST266, Clinical Trial Description, 2021

Table 50: 7 Major Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 51: 7 Major Market Size of Ocular Hypertension by Therapies in USD Million (2018–2030)

Table 52: 7 Major Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 53: United States Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 54: United States Market Size of Ocular Hypertension of Therapies by Class in USD Million (2018–2030)

Table 55: United States Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 56: Germany Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 57:  Germany Market Size of Ocular Hypertension of Therapies by Class in USD Million (2018–2030)

Table 58:  Germany Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 59: France Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 60:  France Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Table 61:  France Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 62: Italy Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 63:  Italy Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Table 64:  Italy Market Size of Ocular Hypertension of Emerging Therapies in USD Million (2018–2030)

Table 65: Spain Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 66:  Spain Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Table 67:  Spain Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 68: United Kingdom Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 69:  United Kingdom Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Table 70: United Kingdom Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Table 71: Japan Market Size of Ocular Hypertension in USD Million (2018–2030)

Table 72: Japan Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Table 73: Japan Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Prevalent Patient Population of Ocular Hypertension in 7MM (2018–2030)

Figure 2: Prevalent Cases of Ocular Hypertension in the United States (2018–2030)

Figure 3: Gender-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Figure 4: Age-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Figure 5: Treated Cases of Ocular Hypertension in the United States (2018–2030)

Figure 6: Prevalent Cases of Ocular Hypertension in Germany (2018–2030)

Figure 7: Gender-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Figure 8: Age-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Figure 9: Treated Cases of Ocular Hypertension in Germany (2018–2030)

Figure 10: Prevalent Cases of Ocular Hypertension in France (2018–2030)

Figure 11: Gender-specific Prevalence of Ocular Hypertension in France (2018–2030)

Figure 12: Age-specific Prevalence of Ocular Hypertension in France (2018–2030)

Figure 13: Treated Cases of Ocular Hypertension in France (2018–2030)

Figure 14: Prevalent Cases of Ocular Hypertension in Italy (2018–2030)

Figure 15: Gender-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Figure 16: Age-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Figure 17: Diagnosed Cases of Ocular Hypertension in Italy (2018–2030)

Figure 18: Prevalent Cases of Ocular Hypertension in Spain (2018–2030)

Figure 19: Gender-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Figure 20: Age-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Figure 21: Treated Cases of Ocular Hypertension in Spain (2018–2030)

Figure 22: Prevalent Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 23: Gender-specific Prevalence of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 24: Age-specific Prevalence of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 25: Treated Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 26: Prevalent Cases of Ocular Hypertension in Japan (2018–2030)

Figure 27: Gender-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Figure 28: Age-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Figure 29: Treated Cases of Ocular Hypertension in Japan (2018–2030)

Figure 30: 7 Major Market Size of Ocular Hypertension in USD Million (2018–2030)

Figure 31: 7 Major Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Figure 32: 7 Major Market Size of Ocular Hypertension for Emerging Therapies by class in USD Million (2018–2030)

Figure 33: Market Size of Ocular Hypertension in the United States, USD Million (2018–2030)

Figure 34: The United States Market Size of Ocular Hypertension of Therapies by class in USD Million

Figure 35: The United States Market Size of Ocular Hypertension for Emerging Therapies in USD Million

Figure 36: Market Size of Ocular Hypertension in the Germany, USD Million (2018–2030)

Figure 37: The Germany Market Size of Ocular Hypertension of Therapies by Class in USD Million

Figure 38: The Germany Market Size of Ocular Hypertension for Emerging Therapies in USD Million

Figure 39: Market Size of Ocular Hypertension in the France, USD Million (2018–2030)

Figure 40: The France Market Size of Ocular Hypertension of Therapies by Class in USD Million

Figure 41: The France Market Size of Ocular Hypertension for Emerging Therapies in USD Million

Figure 42: Market Size of Ocular Hypertension in the Italy, USD Million (2018–2030)

Figure 43: The Italy Market Size of Ocular Hypertension of Therapies by class in USD Million

Figure 44: The Italy Market Size of Ocular Hypertension of Emerging therapies in USD Million

Figure 45: Market Size of Ocular Hypertension in the Spain, USD Million (2018–2030)

Figure 46: The Spain Market Size of Ocular Hypertension of Therapies by class in USD Million

Figure 47: The Spain Market Size of Ocular Hypertension for Emerging Therapies in USD Million

Figure 48: Market Size of Ocular Hypertension in the United Kingdom, USD Million (2018–2030)

Figure 49: The United Kingdom Market Size of Ocular Hypertension of Therapies by class in USD Million (2018–2030)

Figure 50: The United Kingdom Market Size of Ocular Hypertension for Emerging Therapies in USD Million (2018–2030)

Figure 51: Market Size of Ocular Hypertension in the Japan, USD Million (2018–2030)

Figure 52: The Japan Market Size of Ocular Hypertension of Therapies by Class in USD Million

Figure 53: The Japan Market Size of Ocular Hypertension for Emerging Therapies in USD Million

• Travoprost ophthalmic solution

• Vyzulta (latanoprostene bunod ophthalmic solution)

• Zioptan

• Rhopressa

• DURYSTA

• Rocklatan

• LUMIGAN

• Betaxon

• COSOPT

• Rescula

• Alphagan P

• Xelpros

• Tapcom/ DE-111

• Simbrinza

• GLANATEC

• DuoTrav PQ (travoprost/timolol)

• Combigan

• Azarga

• Ganfort

• Mikeluna

• Aibeta

• DE-130A (latanoprost)

• NCX 470

• Bamosiran (SYL040012)

• Nyxol (Phentolamine Mesylate)

• POLAT-001

• Sepetaprost (DE-126/ONO-9054)

• ENV515 (Travoprost XR)

• PRO-122

• DE-117

• PDP-716

• QLS-101

• ST266

  • Tags:
  • Ocular Hypertension market
  • Ocular Hypertension market researc...
  • Ocular Hypertension market insight
  • Ocular Hypertension market trends
  • Ocular Hypertension market forecas...
  • Ocular Hypertension market share
  • Ocular Hypertension pipeline drugs
  • Ocular Hypertension treatment algo...
  • Ocular Hypertension drugs
  • Ocular Hypertension sales forecast...
  • Ocular Hypertension market size
  • Ocular Hypertension disease
  • Ocular Hypertension epidemiology
  • Ocular Hypertension

Forward to Friend

Need A Quote